Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
DK McGuire, WJ Shih, F Cosentino… - JAMA …, 2021 - jamanetwork.com
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the
class remains uncertain. Objective To perform meta-analyses that assess the CV and kidney
outcomes of all 4 available SGLT2 inhibitors in patients with type 2 diabetes. Data Sources A
systematic literature search was conducted in PubMed from January 1, 2015, to January 31,
2020. Study Selection One hundred forty-five records were initially identified; 137 were …
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the
class remains uncertain. Objective To perform meta-analyses that assess the CV and kidney
outcomes of all 4 available SGLT2 inhibitors in patients with type 2 diabetes. Data Sources A
systematic literature search was conducted in PubMed from January 1, 2015, to January 31,
2020. Study Selection One hundred forty-five records were initially identified; 137 were …
